FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and concerns a bispecific antibodies that specifically bind a T-cell activating antigen and a tumor antigen (TA), comprising a first Fab fragment and a second Fab fragment, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody does not comprise a Fc domain, so that the constant region of the heavy chain consists of one or more CH1 domains. Group of inventions also relates to a host cell, comprising vectors comprising nucleic acid molecules, encoding the light chains and heavy chains of the bispecific antibody; application of bispecific antibody in preparing a drug for treating cancer.
EFFECT: group of inventions provides inducing T cell-mediated apoptosis of target cells.
19 cl, 9 ex, 23 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| BIOSPECIFIC ANTIGEN-BINDING MOLECULES | 2012 |
|
RU2650775C2 |
| ANTIBODIES WITHOUT Fc-FRAGMENT INCLUDING TWO FAB-FRAGMENT AND METHODS OF APPLICATION | 2012 |
|
RU2617970C2 |
| ANTIBODIES BINDING TO HLA-A2/WT1 | 2018 |
|
RU2815176C2 |
| NEW BISPECIFIC ANTIGEN-BINDING MOLECULES WITH CAPABILITY OF SPECIFICALLY BINDING TO CD40 AND FAP | 2018 |
|
RU2766234C2 |
| ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| ANTIBODIES BINDING TO CD3 | 2019 |
|
RU2810924C2 |
| BISPECIFIC ANTIBODY MOLECULES AND ANTIGEN TRANSFECTED T-CELLS, AND THEIR USE IN MEDICINE | 2013 |
|
RU2693264C2 |
| BISPECIFIC ANTIBODIES | 2011 |
|
RU2573588C2 |
